9.96
0.15 (1.53%)
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Mixed | Bearish |
Biotechnology (Global) | Mixed | Bearish | |
Stock | Mineralys Therapeutics, Inc. | Mixed | Bearish |
Stockmoo Score
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic. |
|
Sector | Healthcare |
Industry | Biotechnology |
Ownership
Name | Date | Shares Held |
---|---|---|
Adams Street Partners Llc | 30 Jun 2024 | 1,688,712 |
52 Weeks Range | ||
Median | 30.00 (201.21%) | |
Total | 1 Buy |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
HC Wainwright & Co. | 15 Aug 2024 | 30.00 (201.20%) | Buy | 9.76 |
10 Jul 2024 | 30.00 (201.20%) | Buy | 13.10 |
No data within this time range.
Date | Type | Details |
---|---|---|
28 Aug 2024 | Announcement | Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference |
13 Aug 2024 | Announcement | Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update |
05 Aug 2024 | Announcement | Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024 |
14 Jun 2024 | Announcement | Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |